Get the Stockscreener App
2.73
4.60%
0.12
Protalix BioTherapeutics Inc. stock is traded at $2.73, with a volume of 700.90K.
It is up +4.60% in the last 24 hours and up +2.63% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$2.61
Open:
$2.63
24h Volume:
700.90K
Relative Volume:
0.66
Market Cap:
$219.96M
Revenue:
$52.74M
Net Income/Loss:
$-6.60M
P/E Ratio:
-32.31
EPS:
-0.0845
Net Cash Flow:
$-13.63M
1W Performance:
+1.11%
1M Performance:
+2.63%
6M Performance:
+14.71%
1Y Performance:
+9.64%
1-Day Range:
$2.62
$2.745
1-Week Range:
$2.61
$2.80
52-Week Range:
$1.60
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.73 | 219.96M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
508.43 | 128.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.56 | 94.84B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.54 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.87 | 53.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
PLX S-8及美國證券交易委員會申報文件 - Yahoo 財經
Director at Protalix (NYSE: PLX) gets options expiring 2036 plus 8,500 RSUs - Stock Titan
PLX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Protalix BioTherapeutics Grants 168,000 Derivative Securities to Executive Naos Yaron (AMEX: PLX) - Kalkine Media
Protalix BioTherapeutics (AMEX: PLX) Grants 25,500 Derivative Securities to Insider Forster Eliot - Kalkine Media
Protalix CFO is scheduled for two New York appearances this month - Stock Titan
Stock awards for Protalix (PLX) director vest quarterly to 2036 - Stock Titan
Protalix (NYSE: PLX) director receives new options and RSUs - Stock Titan
Protalix (NYSE: PLX) sets CEO equity to 3-year vesting, change-in-control terms - Stock Titan
Board member at Protalix (PLX) gets new stock and option grant - Stock Titan
Yaron Naos awarded new equity at Protalix BioTherapeutics (PLX) - Stock Titan
Director at Protalix BioTherapeutics (PLX) gets new options and stock units - Stock Titan
Protalix (PLX) awards Amos Bar‑Shalev new 3‑year equity grant - Stock Titan
Protalix BioTherapeutics (PLX) awards director new equity grants - Stock Titan
PLX Stock Price, Quote & News - Syfe
Zacks Research Issues Pessimistic Outlook for PLX Earnings - MarketBeat
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs - Kalkine Media
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PLX: Elfabrio Estimates Up - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ... - Yahoo! Finance Canada
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highl - GuruFocus
Earnings call transcript: Protalix posts stronger Q2 2026 revenue, shares slip premarket - Investing.com
Protalix BioTherapeutics Inc (PLX) Reports Q2 Earnings: $19.8M R - GuruFocus
Protalix BioTherapeutics, Inc. (PLX) Q2 FY2026 earnings call transcript - Yahoo Finance
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com South Africa
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com Australia
Protalix BioTherapeutics reports Q2 revenue gro... - Pluang
Protalix BioTherapeutics, Inc. 2026: Revenue $19.9M, EPS $0.05— 10-Q Summary - TradingView
Protalix BioTherapeutics (PLX) swings to $22.1M H1 profit on Elfabrio milestone - Stock Titan
Protalix Posts $19.9 Million Q2 Revenue and $3.8 Million Net Income - Quiver Quantitative
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Protalix BioTherapeutics reports $53.6M YTD revenue, $22.1M net income in H1 2026 - TradingView
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com UK
Protalix: Q2 Earnings Snapshot - 10TV
Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026 - marketscreener.com
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results - PR Newswire
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 - PR Newswire
Protalix BioTherapeutics (PLX) Slips 1% as Shares Hover Between Support and ResistanceFloat Adjusted Cap - dars.gov.et
Protalix BioTherapeutics, Inc. Share Price Live Today – AMEX:PLX Stock Price, Chart, News, History - Upstox
Earnings Preview: PLX to Report Financial Results Pre-market on August 12 - Moomoo
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 - Morningstar
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 - Yahoo Finance
Protalix BioTherapeutics (PLX) Edges Higher Amid Consolidation Near SupportRetail Driven Moves - vinanet.vn
BlackRock (NYSE: BLK) discloses 5.02% ownership in Protalix BioTherapeutics (PLX) - Stock Titan
Protalix Biotherapeutics Inc (PLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protalix BioTherapeutics Inc. Stock (PLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bar-Shalev Amos | Director |
Nov 18 '25 |
Sale |
1.87 |
168 |
314 |
0 |
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):